CME: HR+/HER2-Negative Breast Cancer: Revolutions in Precision Medicine with PI3K Inhibitors

Be part of the knowledge.

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
10857 Axis Breast Cancer CME

HR+/HER2-Negative Breast Cancer: Revolutions in Precision Medicine with PI3K Inhibitors

Program Information
HR+/HER2-Negative Breast Cancer: Revolutions in Precision Medicine with PI3K Inhibitors
An expert reviews the latest evidence-based findings on the use of PI3K inhibitors for patients with metastatic breast cancer.

Available credits: 0.50

Time to complete: 30 Minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Approximately 40% of patients with HR+ breast cancer harbor PIK3CA mutations, which are associated with a poor prognosis. The phosphoinositide 3-kinase (PI3K) pathway is the most frequently altered pathway in breast cancer and has been associated with resistance to endocrine therapy and disease progression. PI3K inhibitor combination therapy has shown activity in patients with PIK3CA mutation–positive HR+/HER2− breast cancer after showing moderate efficacy and limited tolerability in clinical trials as monotherapy.

    This activity will review the most recent clinical data and evidence-based updates and provide expert insights on PI3K inhibitors for HR+/HER2− advanced or metastatic breast cancer.

  • Learning Objectives

    At the conclusion of this activity, participants should be better able to:

    • Describe the PI3K pathway, and the significance of PIK3CA mutations in HR+/HER2− breast cancer
    • Analyze data supporting the use of PI3K inhibitor treatment strategies for HR+/HER2− advanced or metastatic breast cancer
    • Discuss the importance of precision medicine and genomic testing to identify patients with PIK3CA mutations who would benefit from treatment with a PI3K inhibitor.
  • Target Audience

    This activity is intended for medical oncologists, pathologists, laboratory technicians, advanced practitioners, and other healthcare professionals who treat or manage advanced HR+/HER2-negative breast cancer.

  • Disclosure of Conflicts of Interest

    Disclosure of Conflicts of Interest

    AXIS Medical Education requires instructors, planners, managers, and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

    AXIS will identify, review, and resolve all conflicts of interest that faculty, authors, activity directors, planners, managers, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

    The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

    Name of Faculty or Presenter

    Reported Financial Relationship

    Ingrid A. Mayer, MD


    Ingrid A. Mayer, MD, reported a financial interest/relationship or affiliation in the form of Advisor: Novartis Pharmaceuticals Corp; Genentech, Inc; Eli Lilly and Co; GlaxoSmithKline; MacroGenics, Inc; Seattle Genetics, Inc; Immunomedics, Inc; and AstraZeneca Pharmaceuticals LP. Research grant: Pfizer, Inc; and Genentech, Inc.

    Robert Mocharnuk, MD

    Robert Mocharnuk, MD, reported a financial interest/relationship or affiliation in the form of Common stock: Merck.


    The following AXIS planners and managers, Jocelyn Timko and Marilyn Haas, PhD, RN, CNS, ANP-BC hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months.  Linda Gracie-King, MS (spouse) reports a financial interest/relationship or affiliation in the form of Common stock: Exelixis. Robert Mocharnuk, MD, reports a financial interest/relationship or affiliation in the form of Common stock: Merck.



  • Accreditation and Credit Designation Statements


    Accreditation Statement

    In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.

    Credit Designation for Physicians

    AXIS Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™.

    Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Credit Designation for Nursing

    AXIS Medical Education designates this continuing nursing education activity for 0.5 contact hours.

    Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

    AXIS Contact Information

    For information about the certification of this activity, please contact AXIS at

  • Provider(s)/Educational Partner(s)

    Provided by 

  • Commercial Support

    This activity is supported by an educational grant from Novartis Pharmaceuticals.

  • Terms of Use

    Disclosure of Unlabeled Use                                  

    This educational activity may contain discussion of agents that are not approved for use by the FDA and/or investigational (“off-label”) uses of agents that are approved by the FDA. The planners of this activity do not recommend the use of any agent outside of its labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each agent for information on its approved indications, contraindications, warnings, and other, related information.

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio


Programs 11/19/19

    Get a Dose of ReachMD in Your Inbox
    and Practice Smarter Medicine

    Stay current with the best in medical education.